Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 270 participants.
Also called NCT07917078
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 270 participants
- Registry
-
NCT07917078
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07917078. Randomized; single masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features
- Acronym
- REDUCTION
- Condition
- Pulmonary Embolism
- Intervention (Drug)
- Alteplase
- Intervention (Drug)
- Standard Anticoagulation
- Lead sponsor
- China National Center for Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct07917078- Content hash
f877fbab28bd8d1d9eb5d9edc8943108f65b69684e5307258f25894f1db3721a